215 related articles for article (PubMed ID: 27492073)
1. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
Nguyen HS; Milbach N; Hurrell SL; Cochran E; Connelly J; Bovi JA; Schultz CJ; Mueller WM; Rand SD; Schmainda KM; LaViolette PS
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2201-2208. PubMed ID: 27492073
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
[TBL] [Abstract][Full Text] [Related]
3. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
[TBL] [Abstract][Full Text] [Related]
5. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
[TBL] [Abstract][Full Text] [Related]
6. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
[TBL] [Abstract][Full Text] [Related]
7. Diffusion restriction associated with bevacizumab treatment in recurrent glial tumors, evaluation of survival with ADC measurement analysis.
Savran B; Göç MF; Öztürk FU; Duran AO; Ünal Ö
Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4153-4161. PubMed ID: 37203841
[TBL] [Abstract][Full Text] [Related]
8. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
[TBL] [Abstract][Full Text] [Related]
9. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.
Zakhari N; Taccone MS; Torres C; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Nguyen TB
AJNR Am J Neuroradiol; 2018 Feb; 39(2):260-264. PubMed ID: 29217742
[TBL] [Abstract][Full Text] [Related]
11. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab.
Toh CH; Liau CT; Wei KC; Castillo M
J Neurooncol; 2019 Mar; 142(1):149-159. PubMed ID: 30535596
[TBL] [Abstract][Full Text] [Related]
12. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
[TBL] [Abstract][Full Text] [Related]
13. The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma.
Barajas RF; Butowski NA; Phillips JJ; Aghi MK; Berger MS; Chang SM; Cha S
Acad Radiol; 2016 Sep; 23(9):1073-82. PubMed ID: 27443507
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma.
Seystahl K; Hentschel B; Loew S; Gramatzki D; Felsberg J; Herrlinger U; Westphal M; Schackert G; Thon N; Tatagiba M; Pietsch T; Reifenberger G; Löffler M; Wick W; Weller M;
J Cancer Res Clin Oncol; 2020 Mar; 146(3):659-670. PubMed ID: 31754832
[TBL] [Abstract][Full Text] [Related]
15. Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.
Gupta A; Young RJ; Karimi S; Sood S; Zhang Z; Mo Q; Gutin PH; Holodny AI; Lassman AB
AJNR Am J Neuroradiol; 2011 Aug; 32(7):1301-1306. PubMed ID: 21596805
[TBL] [Abstract][Full Text] [Related]
16. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients.
Cachia D; Elshafeey NA; Kamiya-Matsuoka C; Hatami M; Alfaro-Munoz KD; Mandel JJ; Colen R; DeGroot JF
J Neurooncol; 2017 Oct; 135(1):75-81. PubMed ID: 28702781
[TBL] [Abstract][Full Text] [Related]
17. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
[TBL] [Abstract][Full Text] [Related]
19. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
20. Early assessment of recurrent glioblastoma response to bevacizumab treatment by diffusional kurtosis imaging: a preliminary report.
Lee CY; Kalra A; Spampinato MV; Tabesh A; Jensen JH; Helpern JA; de Fatima Falangola M; Van Horn MH; Giglio P
Neuroradiol J; 2019 Oct; 32(5):317-327. PubMed ID: 31282311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]